Target of egr1 (toe1) polypeptides for inhibition of hiv
OwnerIan De Belle, Sabina Sperandioinventors
Life of this patent
Estimating the term…
Abstract
Described are methods and compositions for preventing and/or treating HIV infection, as well as in vitro and in vivo methods of inhibiting HIV replication, inhibiting HIV viral transcription, inhibiting the viral Tat protein, and inhibiting HIV LTR expression. The methods involve administering a Target of Egr1 (TOE1) polypeptide, fragment or deletion mutant thereof, either to a subject in need of treatment or to a cell infected with an HIV virus. Compositions may comprise the described polypeptide, or an encoding polynucleotide thereof.
Claims29
An isolated polypeptide comprising an amino acid sequence that is between about 80% and about 100% identical to the sequence of SEQ ID NO:1;
- SEQ ID NO:2;
- SEQ ID NO:3;
- SEQ ID NO:4;
- SEQ ID NO:5;
- SEQ ID NO:6;
- SEQ ID NO:7;
- SEQ ID NO:8;
- SEQ ID NO:9;
- SEQ ID NO:10;
- SEQ ID NO:11;
- SEQ ID NO:12;
- SEQ ID NO:13;
- SEQ ID NO:14;
- SEQ ID NO:15;
- SEQ ID NO:16 or SEQ ID NO:17, or which comprises an amino acid sequence that is between about 80% and about 100% identical to the sequence of a deletion mutant of TOE1 selected from the group consisting of K335/D363;
- K335/D373, K335/D387;
- K335/D402;
- K335/D416;
- K335/D435;
- K335/D443;
- K335/S510;
- E329/D363;
- E329/D373;
- E329/D387;
- E329/D402;
- E329/D416;
- E329/D435;
- E329/D443;
- E329/S510;
- L323/D363;
- L323/D373;
- L323/D387;
- L323/D402;
- L323/D416;
- L323/D435;
- L323/D443;
- L323/S510;
- I321/D363;
- I321/D373;
- I321/D387;
- I321/D402;
- I321/D416;
- I321/D435;
- I321/D443;
- I321/S510;
- N302/D363;
- N302/D373;
- N302/D387;
- N302/D402;
- N302/D416;
- N302/D435;
- N302/D443;
- N302/S510;
- Y283/D435;
- Y283/D443;
- H280/D363;
- H280/D373;
- H280/D387;
- H280/D402;
- H280/D416;
- H280/D435;
- H280/D443;
- H280/S510;
- T229/D363;
- T229/D373;
- T229/D387;
- T229/D402;
- T229/D416;
- T229/D435;
- T229/D443;
- T229/S510;
- L218/D363;
- L218/D373;
- L218/D387;
- L218/D402;
- L218/D416;
- L218/D435;
- L218/D443;
- L218/S510;
- L196/D435;
- L196/D443;
- K111/D363;
- K111/D373;
- K111/D387;
- K111/D402;
- K111/D416;
- K111/D435;
- K111/D443;
- K111/S510;
- T65/D363;
- T65/D373;
- T65/D387;
- T65/D402;
- T65/D416;
- T65/D435;
- T65/D443;
- T65/S510;
- G18/D363;
- G18/D373;
- G18/D387;
- G18/D402;
- G18/D416;
- G18/D435;
- G18/D443;
- G18/S510;
- G8/D363;
- G8/D373;
- G8/D387;
- G8/D402;
- G8/D416;
- G8/D435;
- G8/D443;
- G8/S510;
- S5/D363;
- S5/D373;
- S5/D387;
- S5/D402;
- S5/D416;
- S5/D435;
- S5/D443;
- and S5/S510, wherein the indicated amino acids respectively specify the amino- and carboxy-terminal residues of the deletion mutants based on the sequence of SEQ ID NO:1, including fragments and variants thereof, and wherein the amino acid sequence is not SEQ ID NO:1.
2-6. (canceled)
(canceled)
(canceled)
16-18. (canceled)
A method for treatment or prevention of human immunodeficiency virus (HIV) infection in a mammal in need of such treatment comprising administering to said mammal a polypeptide comprising an amino acid sequence that is between about 80% and about 100% identical to the sequence of SEQ ID NO:1;
- SEQ ID NO:2;
- SEQ ID NO:3;
- SEQ ID NO:4;
- SEQ ID NO:5;
- SEQ ID NO:6;
- SEQ ID NO:7;
- SEQ ID NO:8;
- SEQ ID NO:9;
- SEQ ID NO:10;
- SEQ ID NO:11;
- SEQ ID NO:12;
- SEQ ID NO:13;
- SEQ ID NO:14;
- SEQ ID NO:15;
- SEQ ID NO:16 or SEQ ID NO:17, or which comprises an amino acid sequence that is between about 80% and about 100% identical to the sequence of a deletion mutant of TOE1 selected from the group consisting of K335/D363;
- K335/D373, K335/D387;
- K335/D402;
- K335/D416;
- K335/D435;
- K335/D443;
- K335/S510;
- E329/D363;
- E329/D373;
- E329/D387;
- E329/D402;
- E329/D416;
- E329/D435;
- E329/D443;
- E329/S510;
- L323/D363;
- L323/D373;
- L323/D387;
- L323/D402;
- L323/D416;
- L323/D435;
- L323/D443;
- L323/S510;
- I321/D363;
- I321/D373;
- I321/D387;
- I321/D402;
- I321/D416;
- I321/D435;
- I321/D443;
- I321/S510;
- N302/D363;
- N302/D373;
- N302/D387;
- N302/D402;
- N302/D416;
- N302/D435;
- N302/D443;
- N302/S510;
- Y283/D435;
- Y283/D443;
- H280/D363;
- H280/D373;
- H280/D387;
- H280/D402;
- H280/D416;
- H280/D435;
- H280/D443;
- H280/S510;
- T229/D363;
- T229/D373;
- T229/D387;
- T229/D402;
- T229/D416;
- T229/D435;
- T229/D443;
- T229/S510;
- L218/D363;
- L218/D373;
- L218/D387;
- L218/D402;
- L218/D416;
- L218/D435;
- L218/D443;
- L218/S510;
- L196/D435;
- L196/D443;
- K111/D363;
- K111/D373;
- K111/D387;
- K111/D402;
- K111/D416;
- K111/D435;
- K111/D443;
- K111/S510;
- T65/D363;
- T65/D373;
- T65/D387;
- T65/D402;
- T65/D416;
- T65/D435;
- T65/D443;
- T65/S510;
- G18/D363;
- G18/D373;
- G18/D387;
- G18/D402;
- G18/D416;
- G18/D435;
- G18/D443;
- G18/S510;
- G8/D363;
- G8/D373;
- G8/D387;
- G8/D402;
- G8/D416;
- G8/D435;
- G8/D443;
- G8/S510;
- S5/D363;
- S5/D373;
- S5/D387;
- S5/D402;
- S5/D416;
- S5/D435;
- S5/D443;
- and S5/S510, wherein the indicated amino acids respectively specify the amino- and carboxy-terminal residues of the deletion mutants based on the sequence of SEQ ID NO:1, including fragments or variants thereof, in an amount effective to treat or prevent said infection.
(canceled)
25-26. (canceled)
29-37. (canceled)
A protein transduction domain comprising an amino acid sequence that is between about 80% and about 100% identical to the sequence of SEQ ID NO:15, or a fragment or variant thereof.
Dependencies are inferred from the claim text.